MicroPort Scientific Corporation board of directors announced that, based on unaudited consolidated financial statements currently available to the Board, the Group has recorded a loss attributable to equity shareholders of the Company for the six months ended 30 June 2020 of between USD65 million and USD 70 million, as compared with a profit of USD 65.5 million for the same period of last year. This change was principally attributable to: the year-on-year decrease in the sales revenue of implantable devices such as cardiovascular, CRM, and orthopedic devices due to the significant decline in the number of clinical consultation and surgery brought on by the COVID-19 pandemic; the incentive shares granted to certain employees (including an executive director) pursuant to the Share Award Scheme of the Group during the reporting period; and lack of the one-time investment gain on partial disposal of equity interests in Shanghai MicroPort EP MedTech Co. Ltd. for the same period of last year.